Incyte Corporation (BIT:1INCY)

Market Cap	17.42B
Revenue (ttm)	4.10B
Net Income (ttm)	1.01B
Shares Out	n/a
EPS (ttm)	5.03
PE Ratio	17.20
Forward PE	12.13
Dividend	n/a
Ex-Dividend Date	n/a

Volume	55
Average Volume	47
Open	87.80
Previous Close	88.44
Day's Range	87.80 - 89.24
52-Week Range	47.33 - 94.30
Beta	n/a
RSI	63.27
Earnings Date	Oct 28, 2025

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1991
• Employees: 2,617
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1INCY

Financial Performance

In 2024, Incyte's revenue was $4.24 billion, an increase of 14.76% compared to the previous year's $3.70 billion. Earnings were $32.62 million, a decrease of -94.54%.

Financial numbers in USD